- Bariatric embolization, a new, minimally invasive treatment for obesity produces weight loss and reduces appetite for up to one year, according to a new study published in the journal Radiology.
- Designation Based on Phase 2 SPRINT Trial in Pediatric Patients with NF1 Plexiform Neurofibromas / Selumetinib Is a MEK 1/2 Inhibitor Being Co-Developed by AstraZeneca and Merck
03/29/2019 U.S. FOOD & DRUG ADMINISTRATION -
Government